People's Daily Health Client reporter Wang Zhenya People's Daily Health Client reporter found that more than 50 innovative drugs have received preferential policies and have been accelerated to land in the Boao Lecheng Pilot Zone, allowing difficult and severe patients to have me

People's Daily Health Client reporter Wang Zhenya

People's Daily Health Client reporter found that more than 50 innovative drugs have benefited from preferential policies and have been expedited in the Boao Lecheng Pilot Zone, so that difficult and severe patients have medicines to treat them, including the treatment of melanoma. ’s CTLA-4 drug, brigatinib tablets, a new drug for the treatment of lung cancer, infigratinib, a new drug for the treatment of cholangiocarcinoma, etc.

Children were treated with the innovative drug

in the Lecheng Pioneer Zone. On June 30, the first patient in China was treated with tazerestat at Boao Super Hospital, marking the official entry of the world's first EZH2 inhibitor into clinical use in China.

It often takes several years for new overseas drugs to enter the Chinese market after they are approved. For patients who are "racing" with cancer every day, they can only wait anxiously. In order to solve the huge unmet medical needs, the State Council approved the establishment of the Boao Lecheng International Medical Tourism Pilot Zone in 2013. Here, specific medical institutions in the zone are allowed to import products that have been approved for listing overseas but have not yet been marketed in our country due to urgent clinical needs. Approved drugs that cannot be replaced by domestically registered varieties.

The country’s first prescription for tazerestat was issued at Boao Super Hospital.

Dr. Su Weiguo, Chief Executive Officer and Chief Scientific Officer of Chi-Med Medicine, said: "Epithelioid sarcoma and follicular lymphoma still have many unmet medical needs that urgently need to be addressed. The first patient with tazetostat in China The completion of drug use, taking into account clinical progress and China’s national conditions, will enable domestic patients to benefit from this new mechanism of EZH2 inhibitors at the same time as the world, which is a milestone in improving the current treatment status of epithelioid sarcoma and follicular lymphoma.”

Abroad. Many " orphan drugs " can also be tested in hospitals in the Boao Lecheng Pilot Zone. For example, on June 22, the internationally innovative drug Vosolitide for the treatment of congenital achondroplasia was launched at Hainan Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Five children from Shanghai, Chengdu, Wuhan, and Shandong, with an average age of 5.8 years old, received this batch of drug treatment at the same time.

According to Hainan Daily report, Boao Lecheng Pioneer Zone has established contacts with nearly 80 pharmaceutical and device companies in 18 countries and regions, and has established in-depth cooperative relationships with all the top 30 pharmaceutical and device companies in the world, becoming an international innovative pharmaceutical device entering China. One of the most important passages.

Chen Donghong, chief medical officer of Oconvision Biomedicine (Shanghai) Co., Ltd., wrote in Hainan Daily that the new drug OT-401 was launched at least a year and a half faster than we expected. It has also allowed many patients to take advantage of this innovative new drug as soon as possible.

Oconvision Biomedicine introduced an innovative new drug from the United States in November 2018 for the treatment of chronic non-infectious uveitis involving the posterior segment of the eye - OT-401 (fluocinolone acetonide vitreous implant). Under normal circumstances, if the new drug wants to be launched in China, it must first pass traditional Phase III clinical trials, a process that can take up to three to five years at the earliest.

In August 2019, OT-401 passed the urgent clinical channel in Lecheng Pilot Zone and completed its first application in my country. In December 2020, OT-401 was included in the list of pilot varieties for drug and device clinical real-world data research in the Lecheng Pilot Zone. In April 2021, the marketing registration application for OT-401 was submitted. On June 16, the National Medical Products Administration approved the drug's marketing application. OT-401 became my country's first new drug approved for marketing based on overseas clinical trial data and domestic patient clinical real-world data. From August 2019 to June 2022, it took less than three years for this new drug to be launched in China.

According to Hainan Daily, as of June 23, Boao Lecheng has had 228 first-time applications of imported licensed medical devices, and more than 11,000 people have used licensed medical devices. In the first quarter of this year, Boao Lecheng received approximately 40,000 medical tourists, a year-on-year increase of 60%.